Joseph Stringer, an analyst from Needham, maintained the Buy rating on Annexon Biosciences. The associated price target remains the same with $11.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Joseph Stringer has given his Buy rating due to a combination of factors, including Annexon’s solid financial position and clearly defined clinical milestones. He notes that the company’s year‑end cash of roughly $238M should fund operations into the second half of 2027, comfortably spanning several key data readouts that could revalue the stock.
Stringer also highlights multiple upcoming catalysts across Annexon’s portfolio that, in his view, justify a positive stance. These include ongoing EMA review of tanruprubart in GBS with an FDA filing expected in 2026, Phase 2a proof‑of‑concept data for ANX1502 in CAD in 2026, and late‑stage vonaprument GA Phase 3 topline results anticipated in 4Q26, which he regards as the primary driver for potential upside in 2026.
According to TipRanks, Stringer is a 5-star analyst with an average return of 22.0% and a 45.90% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Stoke Therapeutics, and Rhythm Pharmaceuticals.
In another report released yesterday, Clear Street also maintained a Buy rating on the stock with a $17.00 price target.